 Phase IV, open-label, non comparative, multicenter, previously treated patients PTP clinical trial. Patients with severe or moderate hemophilia B with baseline levels of plasma factor IX 5 activity will participate in this study for both treatment regimens: on demand therapy for acute bleeding episodes and therapy for prophylaxis of bleeding episodes Short-term therapy. 